FSD Pharma Inc. (NASDAQ:HUGE – Get Rating) saw a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 363,300 shares, an increase of 6.5% from the March 15th total of 341,100 shares. Currently, 2.2% of the company's shares are short sold. Based on an average daily volume of 173,600 shares, the short-interest ratio is presently 2.1 days.

Institutional Investors Weigh In On FSD Pharma

An institutional investor recently raised its position in FSD Pharma stock. Susquehanna International Group LLP boosted its stake in FSD Pharma Inc. (NASDAQ:HUGE – Get Rating) by 141.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 53,190 shares of the company's stock after acquiring an additional 31,200 shares during the period. Susquehanna International Group LLP owned 0.14% of FSD Pharma worth $42,000 at the end of the most recent quarter. 1.64% of the stock is currently owned by hedge funds and other institutional investors.

FSD Pharma Stock Performance

Shares of FSD Pharma stock traded up $0.03 during trading on Friday, hitting $1.58. The company's stock had a trading volume of 178,904 shares, compared to its average volume of 171,384. FSD Pharma has a 52 week low of $0.62 and a 52 week high of $2.10. The stock has a 50-day moving average price of $1.61 and a two-hundred day moving average price of $1.14.

FSD Pharma Company Profile

(Get Rating)

FSD Pharma, Inc is a specialty biotech pharmaceutical research and development company. It focuses on developing over time a robust pipeline of FDA-approved synthetic compounds targeting the end cannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system.

Featured Stories

• Get a free copy of the StockNews.com research report on FSD Pharma (HUGE)
• 2 Industrial Strength Dividend Stocks Melting Up
• Proctor & Gamble Is Going To Set A New High
• AutoNation's Plans are Keeping Analysts Around
• Netflix Increases Buybacks: Can It Complete A Reversal In 2023?
• Why Philip Morris May Continue to Beat the Broader Market?

Receive News & Ratings for FSD Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FSD Pharma and related companies with MarketBeat.com's FREE daily email newsletter.